Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Neutral +3

AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER - PR Newswire

👴 Amgen announced the retirement of David M. Reese, Executive Vice President and Chief Technology Officer, effective June 30, 2026.

💼 Dr. Reese joined Amgen in 2005 and previously served as executive vice president of Research and Development from 2018 to 2023.

🧬 During his tenure, he led approvals of innovative medicines and biosimilars while advancing the company's pipeline and discovery research capabilities.

🤖 As inaugural CTO, Reese championed early adoption of technology and artificial intelligence across Amgen's business, particularly in R&D.

🗣️ CEO Robert A. Bradway credited Reese with helping lead Amgen through the shift driven by advances in biology and technology.

⚡ The company is implementing organizational changes effective June 1, 2026, to deepen the integration of science and technology.

🔄 These changes align Amgen's structure with convergent innovation, combining biology, data science, and advanced technologies.

🌍 Strategic adjustments support Amgen's ability to serve more patients around the world through better connectivity across operations.

💊 Amgen continues to focus on developing medicines for cancer, inflammatory conditions, rare diseases, heart disease, and obesity.

📈 The company remains at the cutting edge of innovation using technology and human genetic data to push beyond current medical knowledge.

🏆 Amgen has received honors from Fast Company and Forbes for its innovation and workplace culture.

📉 As a component of both the Dow Jones Industrial Average® and the Nasdaq-100 Index®, the company represents one of the 30 largest non-financial firms.

⚠️ Investors should note that this announcement includes forward-looking statements subject to significant risks and uncertainties.

Bullish Signals
  • David M. Reese, Executive Vice President and Chief Technology Officer at Amgen, led the approval of numerous innovative medicines and biosimilars during his tenure.
  • Under Reese's leadership as inaugural CTO, Amgen encouraged the early adoption of technology and artificial intelligence across all facets of the business, particularly in Research and Development.
  • Amgen's organizational changes effective June 1, 2026, will deepen the integration of science and technology to accelerate the discovery and development of new medicines.
  • CEO Robert A. Bradway noted that the capabilities built under David Reese position Amgen to advance convergent innovation and strengthen their ability to serve patients in the years ahead.
  • Amgen is recognized for innovation and workplace culture, including honors from Fast Company and Forbes.
  • The company remains at the cutting edge of innovation, using technology and human genetic data to push beyond current medical knowledge.
Risk Factors
  • David M. Reese, executive vice president and chief technology officer, is retiring effective June 30, 2026, introducing potential leadership transitions in the critical field of artificial intelligence and R&D.
  • The article includes extensive forward-looking statements regarding outcomes of collaborations with companies like BeOne Medicines Ltd., acquisitions including Horizon Therapeutics plc, and product performance that may not materialize as expected.
  • Actual results could differ materially from projections due to competition from other products including biosimilars, manufacturing difficulties or delays, and global economic conditions resulting from geopolitical relations and government actions.
  • Sales of products are affected by pricing pressure, political and public scrutiny, reimbursement policies imposed by third-party payers such as governments and private insurance plans, and healthcare cost containment trends.
  • Research, testing, pricing, marketing, and other operations are subject to extensive regulation, increasing the risk of compliance costs or operational disruptions.
  • The announcement lacks information on a replacement candidate for Chief Technology Officer until June 30, 2026, creating uncertainty about continuity of Amgen's technology adoption strategy during the interim period.
Full Analysis
Amgen announced on April 22, 2026, the retirement of David M. Reese, M.D., as executive vice president and Chief Technology Officer (CTO), effective June 30, 2026. Dr. Reese, who joined the company in 2005 as a clinical development leader in oncology, previously served as executive vice president of Research and Development from 2018 to 2023. During his tenure, he oversaw the approvals of numerous innovative medicines and biosimilars, advanced a robust pipeline of potential new therapies, and strengthened discovery research capabilities. As the inaugural chief technology officer, Dr. Reese played a pivotal role in encouraging the early adoption of technology and artificial intelligence across all facets of the business, particularly within R&D. Robert A. Bradway, chairman and chief executive officer at Amgen, stated that Dr. Reese recognized early on the impact of advances in biology and technology on the industry and helped lead Amgen through that shift. The capabilities built under Dr. Reese's leadership are designed to advance what the company calls convergent innovation, which brings together biology, data science, and advanced technologies such as artificial intelligence to accelerate the discovery and development of new medicines. This strategic focus aims to strengthen the company's ability to serve patients in the years ahead by better connecting these interactions with how the organization operates. To support this integration of science and technology and align with the evolving adoption of new technologies across the health care ecosystem, Amgen is implementing organizational changes effective June 1, 2026. These changes deepen the integration of biology and technology to support Amgen's ability to serve more patients around the world. Founded over 45 years ago in Thousand Oaks, California, Amgen remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. The company is advancing a broad and deep pipeline of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease, and obesity-related conditions. Amgen has been consistently recognized for its innovation and workplace culture, including honors from Fast Company and Forbes. It is one of the 30 companies comprising the Dow Jones Industrial Average and part of the Nasdaq-100 Index. The press release also includes standard forward-looking statements regarding expectations, benefits of collaborations, potential acquisitions such as ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd., or Horizon Therapeutics plc, and performance metrics like revenues and operating margins. These statements note significant risks and uncertainties that could cause actual results to differ materially from projections, including factors such as clinical and regulatory developments, competition, manufacturing difficulties, global economic conditions, and reimbursement policies.